Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $207000.0.

  • Voyager Therapeutics' Capital Expenditures fell 1976.74% to $207000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 4843.48%. This contributed to the annual value of $3.5 million for FY2024, which is 813.88% up from last year.
  • Voyager Therapeutics' Capital Expenditures amounted to $207000.0 in Q3 2025, which was down 1976.74% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Capital Expenditures peaked at $2.1 million during Q1 2024, and registered a low of $155000.0 during Q4 2024.
  • Over the past 5 years, Voyager Therapeutics' median Capital Expenditures value was $658000.0 (recorded in 2025), while the average stood at $676157.9.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9024.18% in 2021, then skyrocketed by 36343.61% in 2022.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Capital Expenditures stood at $347000.0 in 2021, then surged by 168.88% to $933000.0 in 2022, then dropped by 19.08% to $755000.0 in 2023, then tumbled by 79.47% to $155000.0 in 2024, then soared by 33.55% to $207000.0 in 2025.
  • Its Capital Expenditures stands at $207000.0 for Q3 2025, versus $1.1 million for Q2 2025 and $658000.0 for Q1 2025.